# OnCo record paper-phergain-lancet-2024-update (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-phergain-lancet-2024-update/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-phergain-lancet-2024-update" ;
  schema:name "3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial"@en ;
  schema:description "Later report from the PHERGain trial registered as NCT03161353, in The Lancet (2024); its title describes an updated or longer-term analysis."@en ;
  schema:url <https://onco.cc/key-papers/paper-phergain-lancet-2024-update/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(24)00054-0>, <https://pubmed.ncbi.nlm.nih.gov/38582092/>, <https://europepmc.org/article/MED/38582092>, <https://clinicaltrials.gov/study/NCT03161353> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(24)00054-0> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Pérez-García JM, Cortés J, Ruiz-Borrego M, et al." ;
  onco:trials <https://onco.cc/trials/phergain/> ;
  onco:journals <https://onco.cc/journals/lancet/> .